
STAAR Surgical (STAA) Stock Forecast & Price Target
STAAR Surgical (STAA) Analyst Ratings
Bulls say
Staar Surgical is in a strong position with its focus on a high-demand product, the Implantable Collamer Lens (ICL), which is the only viable surgical option for a significant portion of China's population with myopia. The company's recent record 2Q net sales, continued growth in China, and significant improvement in profitability demonstrates the durability and potential of this market. While the Alcon-related distributor disruptions pose a short-term challenge, the leadership transition from interim Co-CEOs to permanent CEO Warren Foust is a positive development, and the company's strong financial position with no debt and a cash balance over $200M provides flexibility for strategic options.
Bears say
Staar Surgical is heavily reliant on the sales of its ICL products, which constitute almost all of its revenue, and the recent US approval for ICL patient eligibility at age 60 is a notable expansion. However, competition in the phakic lens market is intensifying with other companies pursuing R&D in broader power ranges and lens sizing. Furthermore, the unpredictable near-term seasonality patterns in China pose a risk to Staar's performance and its ability to compete with the dominance of LASIK procedures in the market.
This aggregate rating is based on analysts' research of STAAR Surgical and is not a guaranteed prediction by Public.com or investment advice.
STAAR Surgical (STAA) Analyst Forecast & Price Prediction
Start investing in STAAR Surgical (STAA)
Order type
Buy in
Order amount
Est. shares
0 shares